Integration of Palliative Care into Heart Failure Care: Consensus-Based Recommendations from HFSA Out Now!
2024 | HFSA

Daxor Awarded Additional New Patent for Smart Blood Volume Guidance Technology to Improve Treatment & Outcomes

Industry News In The News

Oak Ridge, TN – January 9, 2024 — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces that the United States Patent and Trademark Office has issued the company a second patent (U.S. Patent No. 11,862,311 B2), safeguarding a distinctive clinical guidance system for blood volume management. This system utilizes unique blood volume metrics and related clinical measures to create support guidance for fluid management interventions. 

“Our new patented system makes fluid management decisions significantly easier – driving better outcomes and empowering clinicians at all levels to make more effective treatment decisions. We are thrilled to add this patent to our family of patents covering key innovations in the use of blood volume analysis for precision fluid treatment guidance,” said Jonathan Feldschuh, Daxor’s Chief Scientific Officer. “This patent protects Daxor’s cutting-edge technology for the use in the most common and costly conditions including heart failure, critical care, hypertension, surgical blood loss and sepsis.”